End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
240 TWD | -0.21% | -2.64% | -13.36% |
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 57% by 2026.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- With an enterprise value anticipated at 4.02 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-13.36% | 623M | - | ||
+11.95% | 98.12B | B | ||
+9.69% | 38.82B | B | ||
-6.10% | 17.66B | B- | ||
-20.02% | 2.24B | D+ | ||
-8.37% | 1.54B | C+ | ||
+29.63% | 1.23B | - | ||
-35.62% | 747M | - | ||
-35.36% | 735M | B- | ||
+24.04% | 494M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 3218 Stock
- Ratings Universal Vision Biotechnology Co., Ltd.